Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC70 | TNBC | Basal A | Bosutinib | Src | nRTK | 1.33 | uM | 12400.17 | 0.5236 | 0.1661 | 1.1992 | |
| HCC70 | TNBC | Basal A | Bosutinib | Src | nRTK | 6.67 | uM | 12400.17 | 0.0728 | -0.7750 | 1.1992 | |
| HCC70 | TNBC | Basal A | Bosutinib | Src | nRTK | 33.3 | uM | 12400.17 | 0.1092 | -0.6845 | 1.1992 | |
| Hs 578T | TNBC | Basal B | Bosutinib | Src | nRTK | 0.000256 | uM | 10694.145 | 0.9222 | 0.9300 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Bosutinib | Src | nRTK | 0.00128 | uM | 10694.145 | 0.9140 | 0.9224 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Bosutinib | Src | nRTK | 0.0064 | uM | 10694.145 | 0.9555 | 0.9604 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Bosutinib | Src | nRTK | 0.032 | uM | 10694.145 | 1.0175 | 1.0153 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Bosutinib | Src | nRTK | 0.16 | uM | 10694.145 | 0.9788 | 0.9813 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Bosutinib | Src | nRTK | 0.8 | uM | 10694.145 | 0.7635 | 0.7761 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Bosutinib | Src | nRTK | 4 | uM | 10694.145 | 0.2490 | 0.0850 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Bosutinib | Src | nRTK | 20 | uM | 10694.145 | 0.0161 | -0.6746 | 2.2732 | |
| Hs 578T | TNBC | Basal B | Bosutinib | Src | nRTK | 100 | uM | 10694.145 | 0.0026 | -0.8541 | 2.2732 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.000256 | uM | 10816.145 | 1.0484 | 1.1256 | 0.7766 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.00128 | uM | 10816.145 | 1.0797 | 1.2075 | 0.7766 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.0064 | uM | 10816.145 | 1.0162 | 1.0418 | 0.7766 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.032 | uM | 10816.145 | 0.9230 | 0.8040 | 0.7766 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.16 | uM | 10816.145 | 1.2218 | 1.5886 | 0.7766 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.8 | uM | 10816.145 | 1.0145 | 1.0374 | 0.7766 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 4 | uM | 10816.145 | 0.4612 | -0.2618 | 0.7766 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 20 | uM | 10816.145 | 0.1122 | -0.8804 | 0.7766 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 100 | uM | 10816.145 | 0.2007 | -0.7471 | 0.7766 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.0000853 | uM | 12319.17 | 0.8682 | 0.4790 | 0.4684 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.000427 | uM | 12319.17 | 0.9216 | 0.6802 | 0.4684 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.00213 | uM | 12319.17 | 0.8508 | 0.4163 | 0.4684 | |
| LY2 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.0107 | uM | 12319.17 | 0.9886 | 0.9515 | 0.4684 |